EAM Global Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

EAM Global Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-104,754	Closed	-$1.7M	–	188
2022 Q1	$1.7M	Buy	+104,754	New	+$1.68M	0.31%	172
2021 Q4	–	Sell	-105,976	Closed	-$1.52M	–	202
2021 Q3	$1.52M	Sell	105,976 -51,089	-33%	-$806K	0.36%	130
2021 Q2	$2.48M	Buy	+157,065	New	+$2.13M	0.69%	53
2020 Q3	–	Sell	-348,249	Closed	-$1.66M	–	140
2020 Q2	$1.66M	Buy	+348,249	New	+$1.39M	0.75%	58
2019 Q2	–	Sell	-180,199	Closed	-$1.47M	–	135
2019 Q1	$1.47M	Hold	180,199	–	–	0.65%	77
2018 Q4	$1.45M	Buy	+180,199	New	+$1.4M	0.8%	52

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM Global Investors's BCRX Position: Q2 2022 in Review

EAM Global Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 104,754 shares — an estimated $1.7M sold.

EAM Global Investors first reported a position in BCRX in Q4 2018 and held it in 6 quarters. The position peaked at $2.48M in Q2 2021. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

EAM Global Investors reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
EAM Global Investors sold 104,754 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $1.7M.
EAM Global Investors first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 6 quarters.
EAM Global Investors's BioCryst Pharmaceuticals position peaked at $2.48M in Q2 2021.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on EAM Global Investors's 13F filing for Q2 2022, filed 12 Aug 2022.